Cardiovascular Clinical Studies

This channel includes news and new technology innovations from cardiovascular clinical trials. These clinical studies include all cardiac subspecialties.

Investigational device designed for Left Atrial Appendage Elimination (LAAX) to reduce the risk of stroke in patients with non-valvular atrial fibrillation

News | Atrial Fibrillation

Biosense Webster Begins Enrollment of Pivotal Trial Evaluating the Laminar Left Atrial Appendage Elimination Device 

February 27, 2024 — Biosense Webster, Inc., a global leader in cardiac arrhythmia treatment and part of Johnson & ...

February 27, 2024

The Ohio State University Wexner Medical Center is the first in central Ohio to take part in a global clinical trial to use a novel therapy to reduce the size of the left ventricle without open-heart surgery

News | Cardiovascular Clinical Studies

Ohio State First in Central Ohio to Use Novel Heart Failure Therapy

February 26, 2024 — More than 6 million Americans live with heart failure, and about half have an enlarged left ...

February 26, 2024

Visualization of the blood vessels in the brain of a patient without early venous filling, meaning without excessive reperfusion of the brain area after removal of the blood clot in the blocked artery.

News | Stroke

Arterial Connections Improve Treatment Outcomes Following Stroke

February 26, 2024 — Ischemic strokes are a major health burden. They occur when a blood vessel that supplies the brain ...

February 26, 2024

Wake Forest University School of Medicine, the academic core of Advocate Health, is expanding another research study to Advocate Christ Medical Center, in Oak Lawn, Illinois, just outside Chicago.

News | Heart Failure

Research Study on Novel Rehab Program for Heart Failure Patients, Led by Wake Forest University School of Medicine, Expands to Advocate Health Site in Chicago

February 22, 2024 — Wake Forest University School of Medicine, the academic core of Advocate Health, is expanding ...

February 22, 2024

First of its kind artificial heart valve now approved by FDA for treatment of tricuspid regurgitation.

News | Cardiovascular Clinical Studies

Henry Ford Health Heart Failure Patient First in Michigan to Receive Breakthrough Device

February 21, 2024 — An 80-year-old woman from Frankenmuth, Michigan is the first Henry Ford Health structural heart ...

February 21, 2024

The Medtronic APOLLO Clinical Trial is evaluating the safety and efficacy of an investigative device called the Intrepid Transcatheter Mitral Valve Replacement System (TMVR) for moderate-to-severe or severe symptomatic mitral regurgitation (MR) in patients who may be unsuitable for approved transcatheter repair or surgery.

News | Structural Heart

Hackensack Meridian Jersey Shore University Medical Center Providing State-of-the-Art Medtronic APOLLO Clinical Trial Treating Heart Valve Disease

February 20, 2024 — As New Jersey’s leading provider of high-quality cardiac procedures and diagnostic testing and an ...

February 20, 2024

The study, titled "Targeted Therapy with Glycogen Synthase Kinase-3 Inhibition for Arrhythmogenic Cardiomyopathy" (TaRGET), will be led by the research team at PHRI and will involve collaboration with multiple organizations in addition to AMO Pharma including the Hearts in Rhythm Organization (HiRO).

News | Pharmaceuticals

AMO Pharma Announces Collaboration with Population Health Research Institute to Advance Proof of Concept Clinical Trial to Assess Efficacy of Tideglusib in Treatment of Arrhythmogenic Cardiomyopathy

February 16, 2024 — AMO Pharma Limited, a privately held clinical-stage specialty biopharmaceutical company focusing on ...

February 16, 2024

Bayer AG and Asklepios BioPharmaceutical, Inc. (AskBio), a subsidiary of Bayer AG, have announced that the first patient has been randomized in GenePHIT (Gene PHosphatase Inhibition Therapy), a Phase II trial of AB-1002, also known as NAN-101, for the treatment of congestive heart failure (CHF).

News | Cardiovascular Clinical Studies

First Patient Randomized in AskBio Phase II Gene Therapy Trial for Congestive Heart Failure Treatment

February 15, 2024 — Bayer AG and Asklepios BioPharmaceutical, Inc. (AskBio), a gene therapy company wholly owned and ...

February 15, 2024

The limited clinical trial represents the first human implantation of a cardiac auscultation sensor device

News | Heart Failure

Canary Completes First-in-Human Trial of Cardiac Auscultation Monitoring Sensor

February 15, 2024 — Canary Medical, a medical data company focused on the development and commercialization of its ...

February 15, 2024

Novel bioresorbable scaffold system being developed for expanded indications

News | Stents Bioresorbable

AI Measures Fat Around the Heart, a Key to Predicting Heart Attacks

February 14, 2024 — Efemoral Medical, developer of advanced interventional bioresorbable therapies, today announced that ...

February 14, 2024

The replacement of regular salt with a salt substitute can reduce incidences of hypertension, or high blood pressure, in older adults without increasing their risk of low blood pressure episodes, according to a study published in the Feb. 2024 issue of the Journal of the American College of Cardiology (JACC).

News | Hypertension

DECIDE-Salt Study Finds Salt Substitutes Help to Maintain Healthy Blood Pressure in Older Adults

February 14, 2024 — The replacement of regular salt with a salt substitute can reduce incidences of hypertension, or ...

February 14, 2024

In a groundbreaking study, researchers from The Texas Heart Institute, Baylor College of Medicine, Texas Children's Hospital, and the University of Texas Health Science Center McGovern Medical School have shed light on the underlying molecular cell states within transplanted pediatric hearts, paving the way for improved treatment strategies and enhancing the longevity of cardiac allografts.

News | Pediatric Cardiology

Revolutionary Genomic Study Sheds Light on Immune Microenvironment in Transplanted Pediatric Hearts

February 13, 2024 — Pediatric heart transplantation has long been hailed as a life-saving intervention for children ...

February 13, 2024

The company’s roster of clinical evidence continues to grow, with data highlights on expediting, broadening, and challenging current guidelines in stroke care

News | Stroke

RapidAI Announces Late-Breaking Abstract Simultaneously Published in NEJM; Highlights Key Data Revealed at ISC 2024

February 13, 2024 — RapidAI, the global leader in developing Artificial Intelligence (AI) and clinical workflow ...

February 13, 2024

Cleerly has announced continued strong scientific evidence supporting the clinical utility of its products, detailing a study published online on Jan. 25, 2024 in the European Heart Journal Cardiovascular Imaging

News | Artificial Intelligence

Results of CERTAIN Study Demonstrate Prominent Effects of Cleerly Products on Changing Clinical Management for Patients Suspected of Coronary Artery Disease

February 13, 2024 — Cleerly, a digital healthcare company focused on artificial intelligence (AI)-driven heart disease ...

February 13, 2024

Millions of patients worldwide could benefit from better long-term outcomes by the company’s expansion into peripheral artery disease

News | Peripheral Artery Disease (PAD)

Sensome Announces Initiation of Clinical Trial Assessing Its Tissue Microsensor Technology in Peripheral Artery Disease

February 12, 2024 — Sensome, a company pioneering the connected medical device revolution with the world’s smallest ...

February 12, 2024